PainCeptor Pharma Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PainCeptor Pharma Corp.
Nothing has arguably hurt pharmaceutical investors and dealmakers quite so often and with such force as novel pain drug development failures. As a result, a once hot field has gone cold. Despite setbacks, great strides have been made in understanding the complex biology of pain. Scientists have discovered numerous new pain pathway targets with the potential for designing effective agents with fewer off-target effects. Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now understand better how to design drug trials that can segment patient populations to demonstrate therapeutic efficacy more precisely, potentially reducing placebo effects and paving the way for an era of personalized pain medicine.
Mark Greener reviews a selection of ion channels currently attracting researchers' attention, demonstrating renewed interest in the clinical and commercial potential of an underexploited therapeutic target
Given the paucity of novel pain drugs and the calamities surrounding Vioxx and OxyContin, Big Pharma has a keen interest in finding alternatives. Working within the G-protein coupled receptor superfamily, Cara Therapeutics hopes to oblige.
The calamitous demise of Vioxx and Celebrex has reinforced the terrific challenges facing companies that hope to develop novel therapies for pain. PainCeptor Pharma Corp. hopes to bring relief for many of the industry's miseries and tackle currently untreated PNS-based pain syndromes by recalibrating the pain management equation to focus on its first term.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.